Martingale Asset Management L P Purchases 6,870 Shares of Theravance Biopharma, Inc. (NASDAQ:TBPH)

Martingale Asset Management L P increased its position in shares of Theravance Biopharma, Inc. (NASDAQ:TBPH) by 14.4% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 54,450 shares of the biopharmaceutical company’s stock after purchasing an additional 6,870 shares during the period. Martingale Asset Management L P owned 0.11% of Theravance Biopharma worth $439,000 at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of TBPH. Quantbot Technologies LP purchased a new position in shares of Theravance Biopharma in the third quarter valued at about $60,000. China Universal Asset Management Co. Ltd. lifted its holdings in Theravance Biopharma by 64.7% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 9,409 shares of the biopharmaceutical company’s stock worth $76,000 after purchasing an additional 3,696 shares in the last quarter. Ballentine Partners LLC purchased a new stake in Theravance Biopharma during the 3rd quarter valued at approximately $104,000. Hsbc Holdings PLC purchased a new stake in Theravance Biopharma during the 2nd quarter valued at approximately $108,000. Finally, XTX Topco Ltd bought a new stake in shares of Theravance Biopharma during the second quarter valued at approximately $129,000. Hedge funds and other institutional investors own 99.10% of the company’s stock.

Theravance Biopharma Stock Performance

Shares of Theravance Biopharma stock opened at $9.84 on Wednesday. The stock has a market cap of $483.83 million, a price-to-earnings ratio of -9.74 and a beta of 0.23. The stock has a 50 day moving average price of $8.76 and a 200-day moving average price of $8.70. Theravance Biopharma, Inc. has a one year low of $7.44 and a one year high of $11.71.

Theravance Biopharma (NASDAQ:TBPH) last posted its quarterly earnings data on Tuesday, November 12th. The biopharmaceutical company reported ($0.26) EPS for the quarter, missing the consensus estimate of ($0.10) by ($0.16). The firm had revenue of $16.87 million for the quarter, compared to analysts’ expectations of $16.11 million. Theravance Biopharma had a negative return on equity of 24.79% and a negative net margin of 78.18%. During the same period in the previous year, the firm earned ($0.17) earnings per share. Sell-side analysts predict that Theravance Biopharma, Inc. will post -1.06 earnings per share for the current fiscal year.

Insider Buying and Selling at Theravance Biopharma

In other news, SVP Rhonda Farnum sold 4,000 shares of the stock in a transaction that occurred on Monday, November 11th. The stock was sold at an average price of $9.00, for a total value of $36,000.00. Following the sale, the senior vice president now directly owns 322,743 shares in the company, valued at approximately $2,904,687. This represents a 1.22 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Company insiders own 6.90% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on TBPH. Leerink Partnrs cut shares of Theravance Biopharma from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, August 6th. Leerink Partners cut Theravance Biopharma from an “outperform” rating to a “market perform” rating and reduced their target price for the stock from $15.00 to $10.00 in a report on Tuesday, August 6th. StockNews.com lowered Theravance Biopharma from a “buy” rating to a “hold” rating in a research note on Saturday, August 10th. HC Wainwright reiterated a “buy” rating and set a $15.00 target price on shares of Theravance Biopharma in a research report on Monday, September 16th. Finally, TD Cowen cut their target price on shares of Theravance Biopharma from $10.00 to $9.00 and set a “hold” rating for the company in a report on Tuesday, August 6th. Four research analysts have rated the stock with a hold rating and two have given a buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $13.75.

About Theravance Biopharma

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.